Arcutis director Welgus sells 4,728 shares

Q: How many ARQT shares did Howard G. Welgus sell, and at what price?

Howard G. Welgus sold 4,728 Arcutis Biotherapeutics, Inc. common shares at $26.93 per share on October 15, 2026. The sale was made under a 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.

Q: What were the exercise prices for Howard G. Welgus's ARQT options?

The three exercised option tranches had exercise prices of $6.5223, $7.5100 and $8.6300 per share, covering 822, 1,018 and 2,254 shares, respectively. The options were fully vested, and the exercises occurred October 15, 2026.

The three exercised option tranches carried exercise prices of $6.5223, $7.5100 and $8.6300 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. director Howard G. Welgus exercised fully vested stock options for 4,094 common shares and sold 4,728 shares on October 15, 2026, at $26.93 per share. The transactions were effected under a 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Welgus Howard G.

Role Director

Sold 4,728 shs ($127K)

Approx. gross sale proceeds $127K

Approx. exercise cost $32K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F2}	822	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F2}	1,018	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F2}	2,254	$0.00	$0.00
Exercise	Common Stock ^F1	822	$6.5223	$5K
Exercise	Common Stock ^F1	1,018	$7.51	$8K
Exercise	Common Stock ^F1	2,254	$8.63	$19K
Sale	Common Stock ^F1	4,728	$26.93	$127K

Holdings After Transaction: Stock Option (right to buy) — 28,656 contracts (Direct); Common Stock — 35,207 shares (Direct)

Footnotes (2)

F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2. The option is fully vested.

Key Figures

Options exercised: 822 shares Exercise price: $6.5223 per share Options exercised: 1,018 shares +5 more

8 metrics

Options exercised 822 shares October 15, 2026; first option tranche

Exercise price $6.5223 per share First option tranche

Options exercised 1,018 shares October 15, 2026; second option tranche

Exercise price $7.5100 per share Second option tranche

Options exercised 2,254 shares October 15, 2026; third option tranche

Exercise price $8.6300 per share Third option tranche

Common shares sold 4,728 shares October 15, 2026

Sale price $26.93 per share October 15, 2026

Key Terms

10b5-1 trading plan, fully vested, Stock Option (right to buy)

3 terms

10b5-1 trading plan financial

"pursuant to a 10b5-1 trading plan adopted on March 13, 2026"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

fully vested financial

"The option is fully vested."

Stock Option (right to buy) financial

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares did Howard G. Welgus sell, and at what price?

Howard G. Welgus sold 4,728 Arcutis Biotherapeutics, Inc. common shares at $26.93 per share on October 15, 2026. The sale was made under a 10b5-1 trading plan adopted March 13, 2026, with a plan end date of June 15, 2027.

What were the exercise prices for Howard G. Welgus's ARQT options?

The three exercised option tranches had exercise prices of $6.5223, $7.5100 and $8.6300 per share, covering 822, 1,018 and 2,254 shares, respectively. The options were fully vested, and the exercises occurred October 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 04:50 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:49 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M⁽¹⁾		822	A	$6.5223	36,663	D
Common Stock	10/15/2026		M⁽¹⁾		1,018	A	$7.51	37,681	D
Common Stock	10/15/2026		M⁽¹⁾		2,254	A	$8.63	39,935	D
Common Stock	10/15/2026		S⁽¹⁾		4,728	D	$26.93	35,207	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.5223	10/15/2026		M⁽¹⁾			822	⁽²⁾	11/20/2029	Common Stock	822	$0	5,752	D
Stock Option (right to buy)	$7.51	10/15/2026		M⁽¹⁾			1,018	⁽²⁾	05/31/2033	Common Stock	1,018	$0	7,126	D
Stock Option (right to buy)	$8.63	10/15/2026		M⁽¹⁾			2,254	⁽²⁾	06/14/2034	Common Stock	2,254	$0	15,778	D

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

2. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR